642 Participants Needed

High Flow Nasal Therapy for COPD

Recruiting at 30 trial locations
MJ
SY
Gerard J Criner profile photo
Overseen ByGerard J Criner
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Temple University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. It seems you can continue your usual COPD medical care while participating.

What data supports the effectiveness of the treatment High Flow Nasal Therapy for COPD?

Research shows that High Flow Nasal Therapy (HFNT) can improve breathing in COPD patients by helping clear mucus, reducing dead space in the nose and throat, and improving oxygen and carbon dioxide exchange. It is also found to be safe and well-tolerated in patients with COPD exacerbations.12345

How is the treatment myAirvo3 different from other treatments for COPD?

The myAirvo3 treatment, also known as High Flow Nasal Therapy (HFNT), is unique because it delivers a high flow of oxygen through a nasal cannula, which can be more comfortable and effective than traditional oxygen therapy. It helps improve breathing by providing humidified and heated air, which can be particularly beneficial for patients with COPD who experience difficulty in breathing.14678

What is the purpose of this trial?

Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.

Eligibility Criteria

This trial is for COPD patients aged 40+, who've had a severe exacerbation requiring hospitalization in the past 6 weeks. They must be able to use myAirvo 3 at home, record daily symptoms, and commit to the study's duration. Smokers with a ≥10 pack-year history can join if they meet specific lung function criteria (GOLD stages II-IV). Exclusions include certain sleep apnea scores, recent investigational drug use, life expectancy under 12 months due to other conditions, oxygen needs over 15 L/min, or inability to tolerate nasal prongs.

Inclusion Criteria

For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation
My breathing difficulty is moderate to severe.
I was hospitalized for a severe COPD flare-up in the last six weeks.
See 11 more

Exclusion Criteria

I have not had a head or neck injury in the last month.
Requirement of oxygen greater than 15 L/min
A STOPBang Questionnaire score > 5
See 6 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive home High Flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care

1-2 years
Regular monitoring visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • myAirvo3
  • Pulse oximeter
Trial Overview The trial tests if High Flow Nasal Therapy (HFNT) using myAirvo 3 plus usual medical care improves outcomes for COPD patients compared to usual care alone. It's a phase III study where participants are randomly assigned into two groups: one receiving HFNT at home and the other not. The treatment lasts between one and two years.
Participant Groups
2Treatment groups
Active Control
Group I: Usual COPD careActive Control1 Intervention
The intervention : A pulse oximeter to record heart rate and pulse oximetry on a daily basis will be provided. A smart phone and charger will also be provided to answer a short questionnaire that queries daily respiratory symptoms plus enter heart rate and pulse oximetry data
Group II: Usual COPD care with use of the myAirvo 3 integrated humidifier and flow generator.Active Control1 Intervention
The intervention is the myAirvo 3 humidifier with integrated flow generator delivered through the Optiflow™ + Duet nasal cannula.

myAirvo3 is already approved in United States for the following indications:

🇺🇸
Approved in United States as myAirvo 3 for:
  • Chronic Obstructive Pulmonary Disease (COPD)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Temple University

Lead Sponsor

Trials
321
Recruited
89,100+

Fisher and Paykel Healthcare

Industry Sponsor

Trials
127
Recruited
11,000+
Dr. Justin Vaughan profile image

Dr. Justin Vaughan

Fisher and Paykel Healthcare

Chief Medical Officer since 2024

MD from the University of Auckland

Lewis Gradon profile image

Lewis Gradon

Fisher and Paykel Healthcare

Chief Executive Officer since 2016

Bachelor of Science in Physics from the University of Auckland, New Zealand

Fisher & Paykel Healthcare

Collaborator

Trials
1
Recruited
640+

Findings from Research

High-flow nasal oxygen therapy (HFNOT) was successfully used in 6 children undergoing 14 endoscopic procedures for upper airway obstruction, demonstrating its effectiveness in this setting.
No intraoperative complications related to oxygenation were observed, indicating that HFNOT is a safe technique for pediatric airway surgery.
Early experience with high-flow nasal oxygen therapy (HFNOT) in pediatric endoscopic airway surgery.Riva, T., Theiler, L., Jaquet, Y., et al.[2018]
In a pilot study involving 10 patients with hypercapnic COPD exacerbations, high-flow nasal therapy (HFNT) was found to be safe and well tolerated, with no increase in carbon dioxide levels or worsening of dyspnea during treatment.
All participants successfully used HFNT for at least 3 days without requiring additional interventions like non-invasive ventilation or intubation, indicating its potential as a supportive therapy in managing COPD exacerbations.
Tolerability and Safety of High-Flow Nasal Therapy in Patients Hospitalized with an Exacerbation of COPD.Pandya, AA., Criner, LH., Thomas, J., et al.[2023]
Transnasal high-flow oxygen therapy (HFNT) was found to be more effective than noninvasive positive pressure ventilation (NIV) in improving oxygen levels and carbon dioxide levels in patients with chronic obstructive pulmonary disease (COPD) and type II respiratory failure, based on a meta-analysis of 12 randomized controlled trials involving 948 patients.
HFNT also demonstrated better comfort and tolerance compared to NIV, without increasing the treatment failure rate, suggesting it could be a promising alternative for respiratory support in these patients.
Transnasal High-Flow Oxygen Therapy versus Noninvasive Positive Pressure Ventilation in the Treatment of COPD with Type II Respiratory Failure: A Meta-Analysis.Liu, W., Zhu, M., Xia, L., et al.[2023]

References

Early experience with high-flow nasal oxygen therapy (HFNOT) in pediatric endoscopic airway surgery. [2018]
Tolerability and Safety of High-Flow Nasal Therapy in Patients Hospitalized with an Exacerbation of COPD. [2023]
Transnasal High-Flow Oxygen Therapy versus Noninvasive Positive Pressure Ventilation in the Treatment of COPD with Type II Respiratory Failure: A Meta-Analysis. [2023]
Comparison of High-Flow Nasal Cannula with Conventional Oxygen Therapy in Patients with Hypercapnic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. [2023]
The Mechanisms of Benefit of High-Flow Nasal Therapy in Stable COPD. [2020]
Effectiveness of high-flow nasal oxygen therapy in management of acute hypoxemic and hypercapnic respiratory failure. [2022]
The Use of High-Flow Nasal Cannula Oxygen Outside the ICU. [2020]
Noninvasive ventilation versus oxygen therapy in patients with acute respiratory failure. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security